No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)(1068 views)(PDF restricted47 views) Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, Francia A, Florio C, Orefice G, Tedeschi G, Bellantonio P, Annunziata P, Grimaldi LM, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Brescia Morra V
Mult Scler (ISSN: 1352-4585, 1477-0970, 1352-4585linking), 2016 Aug; 22(9): 1163-1173.
Keywords: Atorvastatin, Brain Atrophy, Interferon Beta1b, Multiple Sclerosis, Adult, Atorvastatin Calcium Adverse Effects Therapeutic Use, Brain Diagnostic Imaging Drug Effects Pathology, Disability Evaluation, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hydroxymethylglutaryl-Coa Reductase Inhibitors Adverse Effects Therapeutic Use, Immunosuppressive Agents Adverse Effects Therapeutic Use, Interferon Beta-1b Adverse Effects Therapeutic Use, Italy, Magnetic Resonance Imaging, Relapsing-Remitting Diagnostic Imaging Drug Therapy Pathology, Neuropsychological Tests, Patient Dropouts, Time Factors, Treatment Outcome, Atorvastatin Adverse Effects Therapeutic Use, Interferon β1b, Interferon Beta Serine, Placebo, Gadobutrol, Methylprednisolone, Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor, Add On Therapy, Article, Controlled Study, Double Blind Procedure, Drug Efficacy, Drug Safety, Drug Tolerability, Expanded Disability Status Scale, Functional Status, Functional Status Assessment, Infection, Italian (citizen), Major Clinical Study, Multicenter Study, Multiple Sclerosis Functional Composite, Musculoskeletal Disease, Neuroimaging, Neurologic Disease, Nuclear Magnetic Resonance Imaging, Randomized Controlled Trial, Recurrence Risk, Brain Size, Cerebrospinal Fluid, Cognitive Defect, Disease Activity, Disease Course, Drug Dose Increase, Gray Matter, Immunosuppressive Treatment, Mental Performance, Musculoskeletal Infection, T1 Weighted Imaging, T2 Weighted Imaging, White Matter, Clinical Trial, Combination Drug Therapy
Affiliations: *** IBB - CNR ***
Department of Neurosciences, Reproductive and Odontostomatological Sciences, Federico II University of Naples, Italy robertalanzillo@libero.it roberta.lanzillo@unina.it.
National Research Council (CNR) Biostructure and Bioimaging Institute (IBB), Naples Multiple Sclerosis Centre, Italy.
Department of Public Health and Clinical and Molecular Medicine, University of Cagliari, Italy.
Multiple Sclerosis Regional Center, Azienda Ospedaliera "Antonio Cardarelli", Italy.
Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, Italy.
IRCCS Neuromed-Pozzilli (IS), Italy.
Neurology Unit, Fondazione Istituto San Raffaele "G. Giglio", Italy.
Department of Biomedical Advanced Sciences, Federico II University, Italy.
IDC Hermitage Capodimonte, Italy.
Dimensione Ricerca S.r.l., Italy.
References: Not available.
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)